Improving the Reproductive Outcome of Poor Quality Ova by Injection of Autologous Somatic Mitochondria
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01631578 |
Recruitment Status :
Withdrawn
(PI moved from medical center)
First Posted : June 29, 2012
Last Update Posted : August 20, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Low Ovarian Reserve Poor Quality Oocytes | Procedure: Injection of an autologous mitochondria to the oocyte. | Phase 1 Phase 2 |
Maternal age at first delivery constantly rises in developed countries. Oocyte quality decreases with advanced age, thus the rate of age-related infertility continuously increases. Presently oocyte donation is the only prompt solution for this widespread problem. Deterioration of mitochondrial function was suggested as one of the explanations for the age-related deterioration of oocyte quality. The supplementation of the ageing oocyte with autologous mitochondria from dividing somatic cells can be a possible solution for energetic enrichment, without introducing foreign mtDNA.
We established a non-hazardous clinical grade system to prepare functional autologous mitochondria concentrate from the granulosa cells aspirated during oocyte pick up. The mitochondrial preparation was examined and found to be non-toxic. The activity of the respiratory chain was constant and unaffected by age or ovarian response. Moreover, the mtDNA in the mitochondrial preparation was found to be intact in all samples examined, including those from older and low responding patients.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 1 Study of the Impact of Injecting an Autologous Somatic Mitochondrial Concentrate Into Poor Quality Ova. |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | August 2015 |
Actual Study Completion Date : | August 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: Injection of mitochondrial concentrate
A small volume of mitochondrial concentrate will be injected together with the spermatozoon during ICSI.
|
Procedure: Injection of an autologous mitochondria to the oocyte.
In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed. |
Active Comparator: Control
ICSI will be performed conventionally.
|
Procedure: Injection of an autologous mitochondria to the oocyte.
In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed. |
- Oocyte fertilization rate [ Time Frame: one day ]Fertilization rate is assessed the day following oocyte retrieval.
- The rate pace and quality of the early embryonic development [ Time Frame: up to 6 days ]The rate (the proportion of fertilized oocytes developing into embryos), pace of cleavage, and quality (morphological) of the early embryonic development will be assessed during the next 1-6 days (case specific).
- Clinical pregnancy [ Time Frame: within 2 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adequate sperm source and uterine cavity. And one or more of the following:
- Age > 40
- 3 unsuccessful IVF cycles or
- > 75% of embryos in previous cycles with > 20-50% fragments or
- < 50% fertilization rate in previous cycles
Exclusion Criteria:
- Inadequate sperm source. Inadequate uterine cavity.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01631578
Israel | |
Hadassah University Hospital | |
Jerusalem, Israel |
Principal Investigator: | Yoel Shufaro, MD PhD | Hadassah |
Responsible Party: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT01631578 |
Other Study ID Numbers: |
252399- HMO-CTIL |
First Posted: | June 29, 2012 Key Record Dates |
Last Update Posted: | August 20, 2015 |
Last Verified: | August 2015 |
mitochondrial injection |